# Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

> **NCT00418431** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Asociación para Evitar la Ceguera en México**

## Conditions studied

- Central Serous Chorioretinopathy

## Interventions

- **DRUG:** Intravitreal injection of Bevacizumab

## Key facts

- **NCT ID:** NCT00418431
- **Lead sponsor:** Asociación para Evitar la Ceguera en México
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-04
- **Primary completion:** 2006-04
- **Final completion:** 2006-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2024-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418431, "Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00418431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*